Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01217203 · ClinicalTrials.gov registry record · Phase 1
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
A Phase 1 study, sponsored by Innate Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01217203: Completed Phase 1 study, sponsored by Innate Pharma.
NCT01217203 is a Phase 1 study that has completed, run by Innate Pharma. The registered enrollment target is 15 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01217203, a Phase 1 study, has completed, sponsored by Innate Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The primary objective of the clinical study is to evaluate, in patients who experience a first or second relapse of their multiple myeloma, the safety of escalating doses of IPH2101 combined with lenalidomide
Primary Outcome
safety of IPH2101 combined with lenalidomide at different dose levels.
Interventions
- DRUG IPH2101 combined to lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2010-09 |
| Est. Completion | 2014-02 |
| Phase | Phase 1 |
What the finished NCT01217203 record still lists
NCT01217203 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 1 intervention - of which IPH2101 combined to lenalidomide is the first listed.
NCT01217203 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01217203 about?
NCT01217203 is a clinical study titled "Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse". The primary objective of the clinical study is to evaluate, in patients who experience a first or second relapse of their multiple myeloma, the safety of escalating doses of IPH2101 combined with lenalidomide
What is the current status of trial NCT01217203?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2010-09. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01217203?
The interventions under investigation include: IPH2101 combined to lenalidomide (DRUG).
Who is sponsoring clinical trial NCT01217203?
This trial is sponsored by Innate Pharma, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01217203's enrollment target sits among peer trials
15 1798th of 2000 higher than 157 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia